ImmuCell vs Jaguar Health
ICCC and JAGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ICCC and JAGX compare
ImmuCell is the larger company, worth 51 times as much as Jaguar Health ($103M against $2.0M).
Jaguar Health grew revenue faster over the last twelve months (136% versus 8.5% for ImmuCell).
ImmuCell scores higher on the StockData Score (13 against 3 for Jaguar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ICCC | JAGX |
|---|---|---|
| Size and price | ||
| Market cap | $103M | $2.0M |
| Share price | $11.33 | $0.390 |
| Change, 1 year | 110% | −100.0% |
| Change, 5 years | 23.2% | −100% |
| Beta (5Y) | 0.74 | 5.30 |
| Employees | 73 | 47 |
| StockData Score | ||
| Total score | 13 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 142× | – |
| P/S | 3.4× | 0.1× (better) |
| P/B | 3.3× | – |
| EV/EBITDA | 16.3× | – |
| P/FCF | 24.4× | – |
| FCF yield | 4.1% | – |
| Fair value | $11.01 | – |
| Margin of safety | −2.9% | – |
| Growth | ||
| Revenue growth (TTM) | 8.5% | 136% (better) |
| Revenue growth, 5Y average | 12.5% (better) | 4.2% |
| Net income growth (TTM) | −55.3% | – |
| EPS growth (TTM) | −57.9% | – |
| Profitability | ||
| Gross margin | 40.3% | 82.3% (better) |
| Operating margin | 12.6% (better) | −93.1% |
| Net margin | 2.6% | – |
| FCF margin | 13.7% | – |
| Return on equity | 2.6% | – |
| Return on invested capital | 11.1% | – |
| Financial health | ||
| Debt / equity | 0.26 | – |
| Net debt / EBITDA | −0.09 | – |
| Interest coverage | 8.9× (better) | −25.9× |
| Current ratio | 4.75 (better) | 0.69 |
| Altman Z-score | 5.06 (better) | −18.45 |
| Piotroski F-score | 7 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 14.7% | – |
| Held by insiders | 13.7% | 17.1% |
| Insider net buying, 12 months | $156K | – |
| Short interest, % of float | 0.19% | 4.7% |
Go deeper
- ICCC stock overview
- ICCC income statement
- ICCC valuation and score
- JAGX stock overview
- JAGX income statement
- JAGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.